CXCR4 and neoplasm: Previously, a couple of clinical trials investigated the safety of continuous intravenous administration of another CXCR4 antagonist (plerixafor) and its impact on the tumor microenvironment (NCT02179970, NCT03277209) in patients with solid tumors.